Novel treatments in pipeline for diabetic eye disease

Conference|AAO

Patrik De Haes, MD, CEO of Oxurion NV, shares the latest updates in clinical studies at the OIS@AAO meeting in Chicago, Oct. 2018.


Patrik De Haes, MD, CEO of Oxurion NV, shares the latest updates in clinical studies at the OIS@AAO meeting in Chicago, Oct. 2018.

Related Videos
Related Content

Retinal scans provide a non-invasive, inexpensive method to track aging

March 30th 2023

Integrating AI to manage DR in a primary care setting

December 1st 2020

COPHy 2023: Debating the value of home monitoring as a management option for AMD

March 25th 2023

What to expect from virtual AAO 2020

November 5th 2020

Early detection and treatment of DR and DME are essential

March 18th 2023

LumiThera reveals sustained vision improvement for 24 months in dry AMD clinical trial data

March 17th 2023

Retinal scans provide a non-invasive, inexpensive method to track aging

March 30th 2023

Integrating AI to manage DR in a primary care setting

December 1st 2020

COPHy 2023: Debating the value of home monitoring as a management option for AMD

March 25th 2023

What to expect from virtual AAO 2020

November 5th 2020

Early detection and treatment of DR and DME are essential

March 18th 2023

LumiThera reveals sustained vision improvement for 24 months in dry AMD clinical trial data

March 17th 2023

Retinal scans provide a non-invasive, inexpensive method to track aging

March 30th 2023

Integrating AI to manage DR in a primary care setting

December 1st 2020

COPHy 2023: Debating the value of home monitoring as a management option for AMD

March 25th 2023

What to expect from virtual AAO 2020

November 5th 2020

Early detection and treatment of DR and DME are essential

March 18th 2023

LumiThera reveals sustained vision improvement for 24 months in dry AMD clinical trial data

March 17th 2023
© 2023 MJH Life Sciences

All rights reserved.